24 November 2020 - - Canada-based clinical-stage biotechnology company Symvivo Corp has entered into a research collaboration with US-based healthcare company Johnson and Johnson's (NYSE: JNJ) Janssen Biotech, Inc businesss, the company said.

Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo's bacTRL platform technology.

The agreement was facilitated by Johnson and Johnson Innovation.

Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases.

Symvivo's bacTRL platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient's own cells to produce therapeutic proteins.

Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology (NCT04025307), immunology and protein therapy. Symvivo is headquartered in Burnaby, British Columbia.